康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002773 康弘药业

已收盘 12-17 15:00:00

{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":30.31,"timestamp":1765955034000,"preClose":29.89,"halted":0,"volume":3749978,"delay":0,"changeRate":0.0141,"floatShares":687000000,"shares":921000000,"eps":1.3573,"marketStatus":"已收盘","change":0.42,"latestTime":"12-17 15:00:00","open":30,"high":30.49,"low":29.7,"amount":113000000,"amplitude":0.0264,"askPrice":30.31,"askSize":69,"bidPrice":30.3,"bidSize":12,"shortable":0,"etf":0,"ttmEps":1.3573,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":29.89,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":32.88,"lowLimit":26.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921320954,"isCdr":false,"pbRate":3,"roa":"--","peRate":22.331099,"roe":"11.55%","epsLYR":1.3,"committee":-0.644764,"marketValue":27925000000,"turnoverRate":0.0055,"status":0,"floatMarketCap":20818000000},"requestUrl":"/m/hq/s/002773","defaultTab":"news","newsList":[{"id":"2590505254","title":"康弘药业最新公告：子公司弘基生物收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505254","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590505254?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:09","pubTimestamp":1765541397,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司子公司成都弘基生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展糖尿病黄斑水肿（DME）、糖尿病视网膜病变（DR）的临床试验。KH658眼用注射液是弘基生物自主研发的基因治疗创新产品，属于治疗用生物制品1类。药品从研发、临床试验、审评和审批的结果以及时间具有不确定性，敬请广大投资者谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200036078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2589613618","title":"康弘药业：截至目前公司没有流感药","url":"https://stock-news.laohu8.com/highlight/detail?id=2589613618","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589613618?lang=zh_cn&edition=full","pubTime":"2025-12-05 15:06","pubTimestamp":1764918382,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司生产流感药吗？康弘药业回复：尊敬的投资者，您好！截至目前，公司没有题述相关的药品。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500017542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0197","LU2148510915.USD","BK0239","BK0196","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2588807872","title":"康弘药业董事会战略委员会工作细则出炉，强化战略决策与投资管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588807872","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588807872?lang=zh_cn&edition=full","pubTime":"2025-12-04 08:08","pubTimestamp":1764806938,"startTime":"0","endTime":"0","summary":"中访网数据 成都康弘药业集团股份有限公司于近期审议通过了《董事会战略委员会工作细则》，旨在完善公司治理结构，强化战略规划与重大投资决策的科学性。根据细则，战略委员会由五名董事组成，其中至少包含一名独立董事，董事长担任主任委员。细则明确了委员会的决策程序，由下设的战略工作组负责前期准备与提案，委员会会议需三分之二以上委员出席，决议经全体委员过半数通过方为有效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31842850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","LU2148510915.USD","002773","LU1064130708.USD","BK0239","LU1064131003.USD","BK0197"],"gpt_icon":0},{"id":"2586828682","title":"康弘药业：截至2025年11月20日股东户数为29,647户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586828682","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586828682?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:34","pubTimestamp":1764128047,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止目前，公司股东人数多少？康弘药业回复：尊敬的投资者，您好！截至2025年11月20日，公司股东户数为29,647户。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600012435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","LU2148510915.USD","LU1064130708.USD","BK0196","BK0197","002773"],"gpt_icon":0},{"id":"2585461478","title":"康弘药业(002773.SZ)：米拉贝隆缓释片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461478","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585461478?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:18","pubTimestamp":1763986706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康弘药业(002773.SZ)公告，公司近日收到国家药品监督管理局签发的米拉贝隆缓释片的《药品注册证书》，批准注册。米拉贝隆为选择性β3肾上腺素受体激动剂，通过作用于膀胱组织，使膀胱平滑肌松弛。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ)：米拉贝隆缓释片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131003.USD","BK0239","LU2148510915.USD","LU1064130708.USD","BK0196","BK0197","002773"],"gpt_icon":0},{"id":"2582801874","title":"股市必读：康弘药业（002773）11月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582801874?lang=zh_cn&edition=full","pubTime":"2025-11-11 02:11","pubTimestamp":1762798271,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，康弘药业报收于31.6元，上涨1.44%，换手率0.93%，成交量6.39万手，成交额2.01亿元。董秘最新回复投资者： 该公司股票一直下跌，请问贵公司有什么措施保证自己的股票稳定？当日关注点来自交易信息汇总：11月10日主力资金净流出283.81万元，散户资金净流入318.1万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0196","BK0197","BK0239","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2582829346","title":"康弘药业：朗沐已在多国实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2582829346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582829346?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:18","pubTimestamp":1762766292,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！感谢你的耐心回复！贵公司有无进入其他国家的计划？若有，会采用什么策略？谢谢！康弘药业回复：尊敬的投资者，您好！除了在研产品的海外临床试验推进外，公司旗下康柏西普眼用注射液（商品名：朗沐）已在蒙古国、巴基斯坦、中国澳门实现销售，并随中国援外医疗队出征乍得、圭亚那、纳米比亚、多米尼克等国。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2580478866","title":"11月4日康弘药业跌6.79%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478866?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:31","pubTimestamp":1762245096,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日康弘药业跌6.79%创60日新低，收盘报30.87元，换手率2.63%，成交量18.04万手，成交额5.66亿元。重仓康弘药业的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为51.84。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共23家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","002773","BK0239","BK0197","BK0196"],"gpt_icon":0},{"id":"2579299535","title":"图解康弘药业三季报：第三季度单季净利润同比增长7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579299535","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579299535?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:56","pubTimestamp":1761677793,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业2025年三季报显示，公司主营收入36.24亿元，同比上升6.23%；归母净利润10.33亿元，同比上升6.08%；扣非净利润10.24亿元，同比上升6.74%；其中2025年第三季度，公司单季度主营收入11.7亿元，同比上升4.75%；单季度归母净利润3.03亿元，同比上升7.71%；单季度扣非净利润3.01亿元，同比上升7.29%；负债率7.29%，投资收益1106.45万元，财务费用-4152.65万元，毛利率90.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773"],"gpt_icon":0},{"id":"2578658589","title":"康弘药业（002773）披露2022年股票增值权激励计划第三个行权期行权条件达成公告，10月28日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578658589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578658589?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:22","pubTimestamp":1761661329,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，康弘药业报收于32.44元，较前一交易日上涨0.31%，最新总市值为298.88亿元。近日，成都康弘药业集团股份有限公司发布关于2022年股票增值权激励计划第三个行权期行权条件达成的公告。公告显示，本次可行权的激励对象总计1人，可申请行权的股票增值权数量为18万份，占公司总股本的0.0195%。激励对象个人绩效考核结果为S≥9分，满足行权条件。本次行权对公司总股本无影响，不会对财务状况和经营成果产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0197","BK0196","BK0239","002773","LU1064130708.USD"],"gpt_icon":0},{"id":"2578613879","title":"康弘药业：开拓国际市场需应对法规与医疗需求挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2578613879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578613879?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:24","pubTimestamp":1761553470,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好！贵公司开拓国际市场存在那些难点？谢谢！康弘药业回复：尊敬的投资者，您好！开拓国际市场对公司而言是一项系统性工程，需要面对如何更好地适配不同市场的法规环境、如何响应多样化的医疗需求，以及如何实现本地化的高效协同等挑战。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700020935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002773","BK0239","LU1064130708.USD","LU1064131003.USD","159891","BK0196","BK0197"],"gpt_icon":0},{"id":"2578651994","title":"股市必读：康弘药业(002773)股东户数2.49万户，较上期增加3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578651994","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578651994?lang=zh_cn&edition=full","pubTime":"2025-10-27 02:33","pubTimestamp":1761503590,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，康弘药业报收于32.29元，下跌2.3%，换手率1.3%，成交量8.91万手，成交额2.89亿元。来自：截至10月20日股东户数增至2.49万户，环比增长3.53%，筹码趋于分散。股本股东变化股东户数变动截至2025年10月20日，康弘药业股东户数为2.49万户，较10月10日增加848.0户，增幅3.53%。户均持股数量由上期的3.83万股下降至3.7万股，户均持股市值为126.07万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0197","BK0239","LU1064131003.USD","002773","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2577550737","title":"康弘药业：截至2025年10月20日股东户数为24,892户","url":"https://stock-news.laohu8.com/highlight/detail?id=2577550737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577550737?lang=zh_cn&edition=full","pubTime":"2025-10-24 11:33","pubTimestamp":1761276802,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)10月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止10月20日股东数是多少？谢谢！康弘药业回复：尊敬的投资者，您好！截至2025年10月20日，公司股东户数为24,892.户。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400015578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064131003.USD","BK0239","002773","LU1064130708.USD","BK0197","LU2148510915.USD"],"gpt_icon":0},{"id":"2575797141","title":"康弘药业：截至2025年10月10日股东户数为24,044户","url":"https://stock-news.laohu8.com/highlight/detail?id=2575797141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575797141?lang=zh_cn&edition=full","pubTime":"2025-10-16 15:04","pubTimestamp":1760598251,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止10月10日最新股东数是多少？谢谢。康弘药业回复：尊敬的投资者，您好！截至2025年10月10日，公司股东户数为24,044户。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600017873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064131003.USD","BK0239","002773","LU1064130708.USD","BK0197","LU2148510915.USD"],"gpt_icon":0},{"id":"2575252860","title":"天风证券：给予康弘药业买入评级，目标价51.84元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575252860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575252860?lang=zh_cn&edition=full","pubTime":"2025-10-14 12:29","pubTimestamp":1760416188,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松,张中华近期对康弘药业进行研究并发布了研究报告《眼科药物龙头企业，肿瘤药研发塑造第二成长曲线》，给予康弘药业买入评级，目标价51.84元。2015年6月26日，康弘药业正式在深圳证券交易所挂牌上市。考虑到公司作为制药行业的优秀企业，我们看好公司未来发展，首次覆盖，给予“买入”评级，给予2025年PE为36X，目标价51.84元/股。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400043696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","601162"],"gpt_icon":0},{"id":"2574146733","title":"康弘药业子公司吸收合并完成 北京弘健注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2574146733","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574146733?lang=zh_cn&edition=full","pubTime":"2025-10-10 12:55","pubTimestamp":1760072130,"startTime":"0","endTime":"0","summary":"中访网数据 成都康弘药业集团股份有限公司宣布，其全资子公司北京康弘生物医药有限公司吸收合并另一全资子公司北京弘健医疗器械有限公司的工商登记手续已办理完成。吸收合并后，北京康弘生物作为存续主体，其公司名称、股权结构、经营范围及注册资本均保持不变，并依法承继北京弘健的全部资产、负债、业务、人员及相关资质。北京弘健已获核准注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251010/31695750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002773","BK0239","BK0197","BK0196","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2574156851","title":"股市必读：康弘药业(002773)股东户数2.4万户，较上期减少3.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574156851","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574156851?lang=zh_cn&edition=full","pubTime":"2025-10-10 08:01","pubTimestamp":1760054491,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2025年10月9日收盘，康弘药业报收于36.66元，下跌1.0%，换手率0.76%，成交量5.19万手，成交额1.92亿元。来自股本股东变化：截至2025年9月30日，康弘药业股东户数环比下降3.67%，户均持股上升至3.84万股，筹码集中度提升。股东户数变动近日康弘药业披露，截至2025年9月30日公司股东户数为2.4万户，较9月19日减少914.0户，减幅为3.67%。户均持股数量由上期的3.7万股增加至3.84万股，户均持股市值为142.18万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251010/31693974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002773","BK0197","BK0239","LU1064130708.USD","LU1064131003.USD","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2574136479","title":"康弘药业：截至2025年9月30日股东户数为23,995户","url":"https://stock-news.laohu8.com/highlight/detail?id=2574136479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574136479?lang=zh_cn&edition=full","pubTime":"2025-10-09 15:51","pubTimestamp":1759996268,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问9月30日收盘后的股东人数是多少？康弘药业回复：尊敬的投资者，您好！截至2025年9月30日，公司股东户数为23,995户。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900016141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","LU1064131003.USD","BK0197","002773","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2571228870","title":"康弘药业(002773.SZ)：依帕司他片取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571228870","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571228870?lang=zh_cn&edition=full","pubTime":"2025-09-29 12:03","pubTimestamp":1759118592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康弘药业(002773.SZ)公告，公司近日收到国家药品监督管理局签发的依帕司他片的《药品注册证书》，批准注册。该药物适应症为：糖尿病性神经病变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ)：依帕司他片取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0239","002773","BK0197"],"gpt_icon":0},{"id":"2570105165","title":"康弘药业：截至2025年9月19日股东户数为24,909户","url":"https://stock-news.laohu8.com/highlight/detail?id=2570105165","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570105165?lang=zh_cn&edition=full","pubTime":"2025-09-25 11:36","pubTimestamp":1758771403,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)09月25日在投资者关系平台上答复投资者关心的问题。投资者提问：最近康弘药业股票价格一直下跌，我想咨询一下，现在的股东人数是多少康弘药业回复：尊敬的投资者，您好！截至2025年9月19日，公司股东户数为24,909户。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500012873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0239","BK0196","BK0197"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765990478922,"stockEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0402},{"period":"3month","weight":-0.2307},{"period":"6month","weight":0.0907},{"period":"1year","weight":0.5568},{"period":"ytd","weight":0.5775}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28410人(较上一季度减少4.17%)","perCapita":"24175股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":"　　成都康弘药业集团股份有限公司的主营业务是药品（包括生物制品、中成药、化学药）和医疗器械（主要是眼科医疗器械）的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}